Latest Tax Incentives News

Papyrus Australia reported a modest net operating cash outflow of $39,000 for May 2025, maintaining a solid cash position supported by available loan facilities that extend its funding runway to over 16 months.

Cann Group Limited has received a $315,552 advance on its expected FY2025 Research and Development Tax Incentive, marking the second tranche of funding to support its ongoing cannabis medicine development.

Lindian Resources has secured a combined $1.65 million cash inflow from the exercise of unlisted options and a government R&D tax refund, strengthening its financial position for advancing the Kangankunde Rare Earths Project.

Chimeric Therapeutics has secured a $2.5 million advance against its FY25 R&D tax incentive, bolstering funding for its clinical trial pipeline and operational needs. This move complements recent capital raises and underscores the company’s strategic financial management amid its oncology-focused cell therapy development.

FireFly Metals has successfully raised approximately A$95 million through a multi-part equity offering to fund an aggressive exploration and development program at its Green Bay Copper-Gold Project in Canada.

Algorae Pharmaceuticals has secured a significant A$318,771 R&D tax incentive rebate from the Australian Taxation Office, providing a non-dilutive cash injection to advance its AI-driven drug discovery programs.

Papyrus Australia has secured a pivotal contract with UniSA to establish a Rapid Prototyping and R&D facility, advancing its sustainable packaging technology and commercial production plans.

Papyrus Australia reported a $52,000 operating cash outflow for April 2025 but bolstered its liquidity with $239,000 in financing inflows, extending its funding runway to over a year.

Amplia Therapeutics reports strong progress in its pancreatic cancer drug development, completing the ACCENT trial recruitment ahead of schedule and initiating a new US trial, while managing a $6.57 million loss for FY25.

The Arkansas Oil & Gas Commission has approved a 2.5% lithium royalty for brine projects, providing Pantera Lithium with regulatory clarity and a competitive fiscal framework that enhances its Smackover Project’s commercial prospects.

Careteq Limited faces a significant repayment demand from the ATO over R&D tax claims but is mounting a formal objection backed by legal counsel.

Noxopharm has secured ethics approval to commence the HERACLES trial, marking the first human study of its novel SOF-SKN™ drug aimed at chronic inflammatory diseases.